Formulation Development and Evaluation of Fast Disintegrating Tablets of Salbutamol Sulphate, Cetirizine Hydrochloride in Combined Pharmaceutical Dosage Form: A New Era in Novel Drug Delivery for Pediatrics and Geriatrics

Table 8

Stability data of Salbutamol Sulphate, Cetirizine Hydrochloride FDT at room temperature and at ambient humidity.

Evaluation parameters	Time interval
	Data of three primary batches on
	0 day			15th day			30th day
	B-1	B-2	B-3	B-1	B-2	B-3	B-1	B-2	B-3
Hardness (Kg/cm^2) ± S.D	1.5 ± 0.29	1.8 ± 0.29	1.5 ± 0.29	1.5 ± 0.00	1.5 ± 0.00	1.7 ± 0.29	1.5 ± 0.00	1.5 ± 0.29	1.5 ± 0.29
Friability (%)	1	0.6	1	0.2	0.3	0.2	0.1	0.1	0.1
Drug content uniformity (mg) ± S.D	SAL-100.8 ± 3.36,; CET-104.7 ± 1.97	SAL-95.6 ± 2.34,; CET-95.4 ± 2.86	SAL-93.8 ± 1.24,; CET-97.7 ± 3.97	SAL-99.5 ± 2.14,; CET-103 ± 1.76	SAL-94.5 ± 2.67,; CET-98.6 ± 2.07	SAL-94.8 ± 1.23,; CET-93.4 ± 1.77	SAL-98.3 ± 1.98,; CET-97.8 ± 2.97	SAL-95.4 ± 1.65,; CET-97.7 ± 2.75	SAL-95.7 ± 3.63,; CET-94.2 ± 2.43
Disintegration time (sec) ± S.D	39 ± 2.28	47 ± 1.80	42 ± 3.01	42 ± 3.97	50 ± 4.52	47 ± 1.66	46 ± 2.83	49 ± 2.52	48 ± 3.75

Average of three determinations/batches.
Average of six determinations/batches.